Medpace (NASDAQ:MEDP) Coverage Initiated at Mizuho

Stock analysts at Mizuho initiated coverage on shares of Medpace (NASDAQ:MEDPGet Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a $435.00 price target on the stock. Mizuho’s target price suggests a potential upside of 11.38% from the stock’s current price.

A number of other equities research analysts also recently issued reports on the stock. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and raised their price target for the company from $340.00 to $450.00 in a report on Tuesday, April 23rd. Robert W. Baird upped their price target on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 price objective on the stock. Finally, UBS Group upgraded Medpace from a “neutral” rating to a “buy” rating and upped their target price for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Medpace has a consensus rating of “Moderate Buy” and a consensus target price of $441.67.

Check Out Our Latest Stock Analysis on Medpace

Medpace Stock Performance

NASDAQ MEDP opened at $390.55 on Tuesday. The company has a market capitalization of $12.10 billion, a PE ratio of 39.81, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40. Medpace has a 52-week low of $199.20 and a 52-week high of $421.00. The company has a 50-day simple moving average of $395.32 and a 200 day simple moving average of $347.47.

Medpace (NASDAQ:MEDPGet Free Report) last issued its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. During the same quarter in the previous year, the firm posted $2.27 EPS. The business’s revenue for the quarter was up 17.7% compared to the same quarter last year. As a group, analysts forecast that Medpace will post 11.29 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the sale, the chief executive officer now directly owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Medpace news, CEO August J. Troendle sold 25,000 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $408.71, for a total value of $10,217,750.00. Following the transaction, the chief executive officer now owns 4,733,019 shares of the company’s stock, valued at $1,934,432,195.49. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 145,291 shares of company stock worth $59,648,117. Company insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Medpace

Several institutional investors have recently made changes to their positions in the business. M&T Bank Corp grew its stake in shares of Medpace by 24.5% during the 3rd quarter. M&T Bank Corp now owns 1,305 shares of the company’s stock valued at $316,000 after acquiring an additional 257 shares during the period. South Dakota Investment Council purchased a new stake in shares of Medpace during the 3rd quarter worth approximately $1,221,000. Atria Investments Inc purchased a new stake in shares of Medpace during the 3rd quarter worth approximately $1,013,000. Zions Bancorporation N.A. grew its holdings in shares of Medpace by 7.9% in the third quarter. Zions Bancorporation N.A. now owns 6,702 shares of the company’s stock valued at $1,623,000 after purchasing an additional 489 shares in the last quarter. Finally, Dorsey Wright & Associates purchased a new position in shares of Medpace in the 3rd quarter worth $2,388,000. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

(Get Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

See Also

Analyst Recommendations for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.